Rachel K. King

Rachel K. King, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Novavax Inc and Crescent Biopharma, Inc. We count 20 filings; the first trade dates from 18 June 2014 and the latest from 12 June 2025.

In open-market terms, that means 4 purchases worth €121k on one side and 2 sales worth €305k on the other. Taken together, the sales exceed the purchases by €185k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 4 share grants and 10 option exercises. 2025 to date brings no purchases and 1 sale.

In size, the median ticket on the buying side is €15k. Across 3 purchases, this insider has always bought alone, with no colleague buying within 30 days.

The latest filing, published on 13 June 2025, reports an option exercise in Novavax Inc. The latest purchase dates back some time: it was published 1,982 days ago, on 21 May 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.